CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of leukocyte biology"
DOI: 10.1002/jlb.5ma0122-467r
Abstract: Small cell lung cancer (SCLC) is characterized by a high relapse rate, drug tolerance, and limited treatment choices. Chimeric antigen receptor (CAR)-modified NK cells represent a promising immunotherapeutic modality for cancer treatment. However, their potential… read more here.
Keywords: dll3; dll3 car; car cells; cancer ... See more keywords